2010
DOI: 10.1128/jcm.00953-10
|View full text |Cite
|
Sign up to set email alerts
|

TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic Approaches

Abstract: The only clinically validated assay available to determine HIV tropism is Trofile, an assay that possesses some limitations. Our first aim was to develop a new phenotypic tropism test (TROCAI [tropism coreceptor assay information]) and to categorize results generated by this test according to the virological response to a short-term exposure to the CCR5 receptor antagonist maraviroc (maraviroc clinical test). Our second aim was to compare TROCAI results to those obtained by Trofile enhanced sensitivity (ES) an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
24
0

Year Published

2011
2011
2015
2015

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 22 publications
(24 citation statements)
references
References 27 publications
0
24
0
Order By: Relevance
“…Plasma samples from 114 HIV-infected individuals screened to be treated with a maraviroc-containing regimen, a subset of samples from the same Seville and Madrid cohorts of patients, were analyzed using the novel deep-sequencing-based HIV-1 coreceptor tropism assay. These results were compared with those from a series of genotypic (population sequencing) and phenotypic (ESTA [42], TROCAI [73], and VeriTrop (Fig. 5B).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Plasma samples from 114 HIV-infected individuals screened to be treated with a maraviroc-containing regimen, a subset of samples from the same Seville and Madrid cohorts of patients, were analyzed using the novel deep-sequencing-based HIV-1 coreceptor tropism assay. These results were compared with those from a series of genotypic (population sequencing) and phenotypic (ESTA [42], TROCAI [73], and VeriTrop (Fig. 5B).…”
Section: Resultsmentioning
confidence: 99%
“…Patients provided written informed consent, and the ethics committee of the hospital approved the study (72). HIV-1 coreceptor tropism in these samples was determined at baseline using two different phenotypic assays, i.e., the enhanced-sensitivity Trofile assay (ESTA) (42) and TROCAI (73), and by population sequencing analyzed with Geno2Pheno (27) with an FPR of 10%, according to the recommenda-tions from the European Consensus Group on the clinical management of HIV-1 tropism testing, as described on the Geno2Pheno website (http: //coreceptor.bioinf.mpi-inf.mpg.de/index.php).…”
Section: Virusesmentioning
confidence: 99%
“…Moreover, the subtype B backbone (HIV-1 NL4-3 ) used to clone the patient-derived gp120/gp41 region was compatible not only with env fragments from subtype B wild-type and multidrugresistant strains but also with that from all non-B HIV-1 group M subtypes analyzed (35). Furthermore, the VERITROP assay is efficient and reproducible, with a turnaround time (11 days) comparable to other phenotypic HIV-1 tropism tests, such as the enhanced-sensitivity Trofile assay (16 days) (42), the RVA Toulouse-TTT (9 days) (57), and TROCAI (21 to 42 days) (53).…”
Section: Discussionmentioning
confidence: 96%
“…A problem with these methods is that prolonged culturing during virus isolation usually leads to changes in the original HIV-1 quasispecies population (52). Thus, a viable alternative has been the use of env recombinant viruses and reporter cell lines expressing HIV-1 receptor and coreceptors to evaluate HIV-1 coreceptor usage (16,18,53), including the only commercially available assay (Trofile; Monogram Biosciences, South San Francisco, CA) (17,42). VERITROP is based on the introduction of patient-derived env fragments into a noninfectious vector using yeast-based cloning (34,35) and a modified version of the ␣-complementation assay for env-mediated cell-to-cell fusion (19).…”
Section: Discussionmentioning
confidence: 99%
“…However, this phenotypic assay has some limitations, including an approximately 20% rate of nonreportable results, and specimens must be shipped to the unique reference laboratory in the United States. For these reasons, other clinical (8), phenotypic (10,11,23), or genotypic (12) alternatives for determining viral tropism have been examined.…”
mentioning
confidence: 99%